Keyword Analysis & Research: quizartinib
Keyword Research: People who searched quizartinib also searched
Search Results related to quizartinib on Search Engine
-
FDA approves quizartinib for newly diagnosed acute myeloid …
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia
Web ResultOn July 20, 2023, the Food and Drug Administration approved quizartinib (Vanflyta, Daiichi Sankyo, Inc.) with standard cytarabine and anthracycline induction and cytarabine consolidation, and as...
DA: 34 PA: 35 MOZ Rank: 65
-
Quizartinib plus chemotherapy in newly diagnosed patients with
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00464-6/fulltext
Web ResultApr 25, 2023 · Quizartinib, an oral, highly potent, selective, type 2 FLT3 inhibitor, plus chemotherapy showed antitumour activity with an acceptable safety profile in patients with FLT3-ITD-positive newly diagnosed AML.
DA: 63 PA: 59 MOZ Rank: 22
-
Quizartinib - Wikipedia
https://en.wikipedia.org/wiki/Quizartinib
Web ResultQuizartinib, sold under the brand name Vanflyta, is an anti-cancer medication used for the treatment of acute myeloid leukemia. It is a small molecule receptor tyrosine kinase inhibitor. Its molecular target is FLT3, also known as CD135 which is a …
DA: 90 PA: 1 MOZ Rank: 3
-
FDA Approves Vanflyta for FLT3-Mutated AML - NCI
https://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-vanflyta-aml-flt3
Web ResultAug 15, 2023 · On July 20, the agency approved quizartinib (Vanflyta) combined with chemotherapy as part of the initial treatment of people with AML that has a specific change in a gene called FLT3. Genetic changes in FLT3 are common in people diagnosed with AML.
DA: 81 PA: 68 MOZ Rank: 43
-
Quizartinib Dihydrochloride - NCI - National Cancer Institute
https://www.cancer.gov/about-cancer/treatment/drugs/quizartinib-dihydrochloride
Web ResultQuizartinib dihydrochloride is approved to treat: Acute myeloid leukemia that is newly diagnosed and has a certain mutation in the FLT3 gene. It is used in adults, first with cytarabine and an anthracycline drug as induction therapy, next with cytarabine as consolidation therapy, and then alone as maintenance therapy.
DA: 10 PA: 86 MOZ Rank: 77
-
Quizartinib Granted Priority Review in the U.S. for Patients with …
https://daiichisankyo.us/press-releases/-/article/quizartinib-granted-priority-review-in-the-u-s-for-patients-with-newly-diagnosed-flt3-itd-positive-acute-myeloid-leukemia
Web ResultOctober 24, 2022. Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone. Tokyo and Basking Ridge, NJ – (October 24, 2022) – Daiichi Sankyo (TSE: 4568) received notification of acceptance by the U.S. Food and Drug …
DA: 82 PA: 98 MOZ Rank: 93
-
Quizartinib: Uses, Interactions, Mechanism of Action - DrugBank …
https://go.drugbank.com/drugs/DB12874
Web ResultSummary. Quizartinib is a FLT3 inhibitor used in combination with cytarabine and anthracycline to treat acute myeloid leukemia with FLT3 internal tandem duplication. Brand Names. Vanflyta. Generic Name. Quizartinib. DrugBank Accession Number. DB12874. Background.
DA: 8 PA: 21 MOZ Rank: 20
-
Quizartinib Uses, Side Effects & Warnings - Drugs.com
https://www.drugs.com/mtm/quizartinib.html
Web ResultNov 28, 2023 · Quizartinib. Generic name: quizartinib [ kwiz-AR-ti-nib ] Brand name: Vanflyta. Dosage form: oral tablet (17.7 mg; 26.5 mg) Drug class: Multikinase inhibitors. Medically reviewed by Drugs.com on Nov 28, 2023. Written by Cerner Multum. Uses. Side effects. Warnings. Before taking. Dosage. Interactions. What …
DA: 2 PA: 90 MOZ Rank: 44
-
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152787/
Web ResultQuizartinib is an oral, highly potent, and selective next-generation FLT3 inhibitor being investigated for the treatment of FLT3-ITD-positive acute myeloid leukaemia. 11 In a phase 1 trial, 12 quizartinib showed complete target inhibition in biomarker assays and clinical activity in FLT3-ITD-positive and FLT3-ITD-negative patients …
DA: 98 PA: 92 MOZ Rank: 54
-
Profile of Quizartinib for the Treatment of Adult Patients with
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955578/
Web ResultJan 8, 2020 · This review focuses on quizartinib, a potent second-generation FLT3 inhibitor. We discuss the clinical trial development, mechanisms of resistance, and the recent FDA decision to deny approval for quizartinib as a single agent in relapsed/refractory AML. Keywords: FLT3, quizartinib, AML, resistance, clinical …
DA: 78 PA: 2 MOZ Rank: 28